FBB Biomed — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

FBB Biomed is pioneering an AI-driven genomic health platform centered on the detection of Endogenous Ancestral Nucleotide Sequences (EANS) from blood. The company is transitioning from research to commercial activity, having recently signed an agreement with a CLIA/CAP-certified lab to offer its first Research Use Only (RUO) test for neurology. Led by a seasoned CEO with a history of diagnostic innovation, FBB aims to revolutionize disease monitoring and patient stratification, starting with neurodegenerative conditions like multiple sclerosis and Parkinson's disease.

NeurologyNeurodegenerative Diseases

Technology Platform

AI Genomics platform analyzing Endogenous Ancestral Nucleotide Sequences (EANS) from blood RNA to measure genomic health and disease activity.

Opportunities

The massive unmet need for non-invasive, repeatable biomarkers in neurodegenerative diseases presents a multi-billion dollar market.

The platform's potential expansion beyond neurology into other complex diseases offers a long-term, scalable opportunity.

Risk Factors

High scientific risk associated with validating the novel EANS theory in large clinical cohorts.

Significant regulatory and commercial execution risk in transitioning from an RUO research tool to an approved clinical diagnostic.

Competitive Landscape

FBB operates in a highly competitive space for liquid biopsies and neurology biomarkers, competing against large diagnostic firms and well-funded startups using proteomics, cell-free DNA, and other genomic approaches. Its differentiation hinges on the unique focus on ancestral RNA sequences.

More companies in Diagnostics & Precision Medicine →More companies in United States →